Advanced vaccine candidates for Lassa Fever

Viruses

Volumn 4, Issue 11, 2012, Pages 2514-2557

  Lukashevich, Igor S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Efficacy in primates; Lassa fever; Pathogenesis; Vaccines

Indexed keywords

ALPHAVIRUS VECTOR; DENGUE VACCINE; DNA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LASSA VIRUS VACCINE; ML29 VACCINE; PEPTIDE VACCINE; POLIOMYELITIS VACCINE; REPLICATION COMPETENT VACCINIA VIRUS VECTOR; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS RNA; VIRUS VACCINE; VIRUS VECTOR; YELLOW FEVER VACCINE;

ANTIBODY TITER; ANTIGEN PRESENTATION; ARENAVIRUS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; ELECTROPORATION; FOOD AND DRUG ADMINISTRATION; GENETIC REASSORTMENT; GENETIC TRANSFECTION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; IMMUNOPATHOGENESIS; INJECTION SITE BLEEDING; INJECTION SITE PAIN; LASSA FEVER; LOW DRUG DOSE; MOLECULAR CLONING; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLIOMYELITIS; PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; SINGLE DRUG DOSE; SMALLPOX; STRAIN DIFFERENCE; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS MUTATION; VIRUS TITRATION; VIRUS TRANSMISSION; VIRUS VIRULENCE; YELLOW FEVER;

AFRICA, WESTERN; ANIMALS; HUMANS; LASSA FEVER; LASSA VIRUS; VIRAL VACCINES;

ARENAVIRIDAE; LASSA VIRUS; MASTOMYS NATALENSIS; PRIMATES; RODENTIA;

EID: 84870603996     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4112514     Document Type: Review

References (220)

1. McCormick, J.B.; Fisher-Hoch, S.P. Lassa fever. Curr. Top. Microbiol. Immuno. l 2002, 262, 75-109.
2. Khan, S.H.; Goba, A.; Chu, M. New opportunities for field research on the pathogenesis and treatment of Lassa fever. Antivir. Res. 2008, 78, 103-115.
3. Fichet-Calvet, E.; Rogers, D.J. Risk Maps of Lassa Fever in West Africa. PLoS Negl. Trop. Dis. 2009, 3, doi: e38810.31371/journal.pntd.0000388.
4. Loureiro, M.E.; Wilda, M.; Levingston-Macleod, J.M. Molecular determinants of Arenavirus Z protein homo-oligomerization and L polymerase binding. J. Virol. 2011, JVI.05691-05611.
5. Richmond, J.K.; Baglole, D. Lassa fever: epidemiology, clinical features, and social consequences. BMJ 2003, 327, 1271-1275.
6. Safronetz, D.; Job, E.; Nafomon, S.; Traore, S.F.; Raffel, S.J.; Fischer, E.R.; Ebihara, H.; Branco, L.; Garry, R.F.; Schwan, T.G.; Feldmann; H. Detection of Lassa Virus, Mali. Emerg. Infect. Dis. 2010, 16, 1123-1126.
7. Andersen, K.G.; Shylakhter, I.; Tabrizi, S.; Grossman, S.R.; Happi, C.T.; Sabeti, P.C. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos. T. R. Soc. B. 2012, 367, 868-877.
8. Sabeti, P.C.; Varilly, P.; Fry, B. Genome-wide detection and characterization of positive selection in human populations. Nature 2007, 449, 913-918.
9. Fisher-Hoch, S.P.; McCormick, J.B. Lassa fever vaccine: A review. Expert. Rev. Vaccines 2004, 3, 103-111.
10. Ishii, A.; Thomas, Y.; Moonga, L.; Nakamura, I.; Ohnuma, A.; Hang'ombe, B.; Takada, A.; Mweene, A.; Sawa, H. Novel arenavirus, Zambia. Emerg. Infect. Dis. 2011, 17, 1921-1924.
11. Salvato, M. S; Clegg, J.C.S.; Buchmeier, M.J. Arenaviridae. In: Virus Taxonomy, VIIIth Report of the ICTV, Fauquet, C.M.; Mayo, M.A.; Maniloff, J.; Desselberger, U.; Ball, L.A. Eds. Elsevier/Academic Press, London, UK, 2005; 725-733.
12. Lukashevich, I.S.; Salvato, M.S. Lassa Virus Genome. Current Genomics 2006, 7, 351-379.
13. Salvato, M. S; Clegg, J.C.S.; Buchmeier, M.J. Arenaviridae. In: Virus Taxonomy, VIIIth Report of the ICTV, Fauquet, C.M.; Mayo, M.A.; Maniloff, J.; Desselberger, U.; Ball, L.A. Eds. Elsevier/Academic Press, London, UK, 2005; 725-733.
14. Salvato, M.S.; Clegg, J.C.S.; Buchmeier, M.J.; Charrel, R.N.; Gonzalez, J.P.; Lukashevich, I.S.; Peters, C.J.; Romanowski, V. Family Arenaviridae, Virus Taxonomy, Classification and Nomenclature of Viruses. Ninth Report of the International Committee on Taxonomy of Viruses. Editors: Andrew King, M.Q.; Adams, M.J.; Carstens, E.B.; Lefkowitz, E.J. Academic Press, Elsevier Inc., Amsterdam, The Netherlands, 2012; pp.715-723.
15. Charrel, R.N.; de Lamballerie, X.; Emonet, S. Phylogeny of the genus Arenavirus. Curr. Opin. Microbiol. 2008, 11, 362-368.
16. Emonet, S. F; de la Torre, J.C.; Domingo, E.; Sevilla, N. Arenavirus genetic diversity and its biological implications. Infect. Genet. Evol. 2009, 9, 417-429.
17. Charrel, R.N.; Lemasson, J.J.; Garbutt, M. New insights into the evolutionary relationships between arenaviruses provided by comparative analysis of small and large segment sequences. Virology 2003, 317, 191-196.
18. Bowen, M.; Rollin, P.; Ksiazek, T. Genetic diversity among Lassa virus strains. J. Virol. 2000, 74, 6992-7004.
19. Lozano, M.E.; Posik, D.M.; Albarino, C.G. Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses. Virus Res. 1997, 49, 79-89.
20. Bowen, M.D.; Peters, C.J.; Nichol, S.T. Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol. Phylogenet. Evol. 1997, 8, 301-316.
21. Gunther, S.; Emmerich, P.; Laue, T. Imported Lassa fever in Germany: molecular characterization of a new Lassa virus strain. Emerg. Infect. Dis. 2000, 6, 466-476.
22. Vieth, S.; Torda, A.E.; Asper, M.; Schmitz, H.; Gunther, S. Sequence analysis of L RNA of Lassa virus. Virology 2004, 318, 153-168.
23. Emonet, S.; Lemasson, J.J.; Gonzalez, J.P.; Lamballerie, X.d.; Charrel, R.N. Phylogeny and evolution of old world arenaviruses. Virology 2006, 350, 251-257.
24. Clegg, J. Molecular phylogeny of the Arenaviridae. Curr. Top. Microbiol. Immunol. 2002, 262, 1-24.
25. Lalis, A.; Leblois, R.; Lecompte, E.; Denys, C.; ter Meulen, J.; Wirth, T. The Impact of Human Conflict on the Genetics of Mastomys natalensis and Lassa Virus in West Africa. PLoS One 2012, 7, e37068.
26. McCormick, J.B.; Fisher-Hoch, S.P. Lassa fever. Curr. Top. Microbiol. Immunol. 2002, 262, 75-109.
27. Peters, C. J; Jahrling, P.B.; Liu, C.T.; Kenyon, R.H.; McKee, K.T.; Oro, J.G.B. Experimental studies of arenaviral hemorrhagic fevers. Curr. Top. Microbiol. Immunol. 1987, 134, 5-68.
28. Swanepoel, R.; Leman, P.A.; Shepherd, A.J.; Shepherd, S.P.; Kiley, M.P.; McCormick, J.B. Identification of Ippy as a Lassa-fever-related virus. Lancet 1985, 1, 639.
29. Meunier, D.Y.; McCormick, J.B.; Georges, A.J.; Georges, M.C.; Gonzalez; J.P. Comparison of Lassa, Mobala, and Ippy virus reactions by immunofluorescence test. Lancet. 1985, 1, 873-874.
30. Gonzalez, J.; McCormick, J.B.; Saluzzo, J.F.; Herve, J.P.; Georges, A.J.; Johnson, K.M. An arenavirus isolated from wild-caught rodents (Pramys species) in the Central African Republic. Intervirol. 1983, 19, 105-112.
31. Wulff, H.B.M.; McIntosh, D.B. Hamner & Johnson, K.M. Isolation of an arenavirus closely related to lassa virus from rodents. Bull. WHO. 1977, 55, 441-444.
32. Johnson, K.M.; Taylor, P; Elliott, L.H.; Tomori, O. Recovery of a Lassa-Related Arenavirus in Zimbabwe. Am. J. Trop. Med. Hyg. 1981, 30, 1291-1293.
33. Georges, A.; Gonzalez, J.P.; Abdul-Wahid, S.; Saluzzo, J.F.; Meunier D.M.; McCormick J.B. Antibodies to Lassa and Lassa-like viruses in man and mammals in the Central African Republic. Trans. R. Soc. Trop. Med. Hyg. 1985, 79, 78-79.
34. Kiley, M.P.; Lange J.V.; Johnson K.M. Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 1979, 2, 738.
35. Walker, D.H.; Johnson, K.M.; Lange, J.V.; Gardner, J.J.; Kiley, M.P.; McCormick, J.B. Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J. Infect. Dis. 1982, 146, 360-363.
36. Fisher-Hoch, S.P.; McCormick, J.B. Lassa fever vaccine. Expert Rev. Vaccines 2004, 3, 103-111.
37. Salazar-Bravo, J.; Ruedas, L.A.; Yates; T.L. Mammalian reservoirs of arenaviruses. Curr. Top. Microbiol. Immunol. 2002, 262, 25-63.
38. Keenlyside R.A.; McCormick, J. B; Webb, P.A.; Smith, E.; Elliott, L.; Johnson, K.M. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am. J. Trop. Med. Hyg. 1983, 32, 829-837.
39. Demby, A.H.; Inapogui, A.; Kargbo, K.; Koninga, J.; Kourouma, K.; Kanu, J.; Coulibaly, M.; Wagoner, K.D.; Ksiazek, T.G.; Peters, C.J.; Rollin, P.E.; Bausch, D.G. Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. Vector Borne Zoonotic Dis. 2001, 1, 283-297.
40. Demartini, J.; Green, D.E.; Monath, T.P. Lassa virus infection of Mastomy natalensis in Sierra Leone. Gros and microscopical findings in infected and uninfected animals. Bull World Health Organ 1975, 52, 651-663.
41. Lecompte, E.; Meulen, J.T.; Emonet, S.; Daffis, S.; Charrel, R.N. Genetic identification of Kodoko virus, a novel arenavirus of the African pigmy mouse (Mus Nannomys minutoides) in West Africa. Virology 2007, 364, 178-183.
42. Paweska, J.; Sewlall N.H.; Ksiazek T.G.; Blumberg L.H.; Hale M.J.; Lipkin. W.I. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg. Infect. Dis. 2009, 15, 1598-1602.
43. Briese, T.; Paweska, J.T.; McMullan, L.K. Genetic Detection and Characterization of Lujo Virus, a New Hemorrhagic Fever-Associated Arenavirus from Southern Africa. PLoS. Pathog. 2009, 4, e1000455.
44. Palacios, G.; Savji, N.; Hui, J. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J. Gen. Virol. 2010, 91, 1315-1324.
45. Coulibaly-N'Golo, D.; Allali, B.; Kouassi, S.K. Novel Arenavirus Sequences in Hylomyscus sp. and Mus (Nannomys) setulosus from Cóte d'Ivoire: Implications for Evolution of Arenaviruses in Africa. PLoS ONE 2011, 6, e20893.
46. Stenglein, M.D.; Sanders, C.; Kistler, A.L. Identification, Characterization, and In Vitro Culture of Highly Divergent Arenaviruses from Boa Constrictors and Annulated Tree Boas: Candidate Etiological Agents for Snake Inclusion Body Disease. mBio 2012, 3, doi:10.1128/mBio.00180-00112.
47. Kerber, R.; Rieger, T.; Busch, C. Cross-species analysis of the replication complex of Old World arenaviruses reveals two sites in nucleoprotein involved in L protein function. J. Virol. 2011, 85, 12518-12528.
48. Lukashevich, I.S. Generation of reassortants between African arenaviruses. Virology 1992, 188, 600-605.
49. Lukashevich, I. S; A.D. Vasiuchkov, T.A.; Stel'makh, E.P.; Scheslenok & Shabanov; A.G. The isolation and characteristics of reassortants between the Lassa and Mopeia arenaviruses. Vopr. Virusol. 1991, 36, 146-150.
50. Cummins, D.; McCormick, J.; Bennett, D. Acute sensorineural deafness in Lassa fever. JAMA. 1990, 264, 2093-2096.
51. Kitching, A.; Addiman, S.; Cathcart, S. A fatal case of Lassa Fever in London, January 2009. EUROSURVEI L LANCE 2009, 14, 1-3.
52. Moraz, M.-L.; Kunz, S. Pathogenesis of arenavirus hemorrhagic fevers. Expert Review of Anti-infective Therapy 2011, 9, 49-59.
53. Baize, S.; Pannetier, D.; Faure, C.; Marianneau, P.; Marendat, I.; Georges-Courbot, M.C.; Deubel, V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 2006, 8, 1194-1202.
54. Baize, S.; Kaplon, J.; Faure, C.; Pannetier, D.; Georges-Courbot, M.C.; Deubel, V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J. Immunol. 2004, 172, 2861-2869.
55. Baize, S.; Marianneau, P; Loth, P. Early and strong immune responses are associated with control of viral replication and recovery in Lassa virus-infected cynomolgus monkeys. J. Virol. 2009, JVI.01948-01908.
56. Hayes, M.W.; Carrion, R.; Nunneley, J.; Medvedev, A.E.; Salvato, M.S.; Lukashevich, I.S. Pathogenic Old World Arenaviruses Inhibit TLR2/Mal-Dependent Pro-Inflammatory Cytokines in vitro. J. Virol. 2012, 86, 7216-7226.
57. Lukashevich, I.S.; Maryankova, R. F.; Vladyko, A.S. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-a gene expression. J. Med. Virol. 1999, 59, 552-560.
58. Mahanty, S.; Bausch, D. G; Thomas, R.L. Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever. J. Infect. Dis. 2001, 183, 1713-1721.
59. Mahanty, S.; Hutchinson, K.; Agarwal, S.; Mcrae, M.; Rollin, P.E.; Pulendran, B. Cutting Edge: Impairment of Dendritic Cells and Adaptive Immunity by Ebola and Lassa Viruses. J. Immunol. 2003, 170, 2797-2801.
60. Meulen, J; Badusche, M.; Satoguina, J. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 2004, 321, 134-143.
61. Ter Meulen, J.; Badusche, M.; Kuhnt, K. Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 2000, 74, 2186-2192.
62. Jahrling, P.B.; Frame, J.D.; Smith, S.B.; Monson, M.H. Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates. Trans. R. Soc. Trop. Med. Hyg. 1985, 79, 374-379.
63. Walker, D.; McCormick, J.B.; Johnson, K.M.; Webb, P.A.; Komba-Kono, G.; Elliott, L.H.; Gardner, J.J. Pathologic and virologic study of fatal Lassa fever in man. Am. J. Pathol. 1982, 107, 349-356.
64. Knobloch, J.M.J.; Webb, P.A.; Dietrich, M.; Schumacher, H.H.; Dennis, E. Clinical observations in 42 patients with Lassa fever. Tropenmed Parasitol. 1980, 31, 389-398.
65. McCormick, J.B.; W. D; King, I.J.; Webb, P.A.; Elliott, L.H.; Whitfield, S.G.; Johnson, K.M. Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am. J. Trop. Med. Hyg. 1986, 35, 401-407.
66. Geisberg, T.W.; Jahrling, P.B. Exotic emerging viral diseases: progress and challenges. Nature Medicine 2004, 10, 110-S121.
67. Ter Meulen, J.; Lukashevich, I.S.; Sidibe, K. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am. J. Trop. Med. Hyg. 1996, 55, 661-666.
68. Dylla, D.E.; Michele, D.E.; Campbell, K.P.; McCray, P.B.; Jr. Basolateral Entry and Release of New and Old World Arenaviruses from Human Airway Epithelia. J. Virol. 2008, 82, 6034-6038.
69. Schlie, K.; Maisa, A.; Freiberg, F.; Groseth, A.; Strecker, T.; Garten, W. Viral Protein Determinants of Lassa Virus Entry and Release from Polarized Epithelial Cells. J. Virol. 2010, 84, 3178-3188.
70. Kunz, S. Receptor binding and cell entry of Old World arenaviruses reveal novel aspects of virus-host interaction. Virology 2009, 387, 245-249.
71. Cosset, F.-L.; Marianneau, P.; Verney, G. Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus Pseudoparticles. J. Virol. 2009, 83, 3228-3237.
72. Lukashevich, I. S; Djavani, M.; Rodas J. D. Hemorrhagic fever occurs after intravenous, but not after intragastric, inoculation of rhesus macaques with lymphocytic choriomeningitis virus. J. Med. Virol. 2002, 67, 171-186.
73. McCormick, J.B. Lassa fever. Factors in Emergence and Control of Rodent-borne Viral Diseases (Hantaviral and Arenal Diseases) 1999, Saluzzo, J.F.; Dodet, B. Eds. Elsevier, Amsterdam, The Netherlands, 1999; pp.177-195.
74. McCormick, J.B.; King, I.J.; Webb P. A. Lassa fever. Effective therapy with ribavirin. N. Engl. J. Med. 1986, 314, 20-26.
75. Fisher-Hoch, S.P. Arenavirus pathophysiology. In: The Arenaviridae. M. S. Salvato (ed), Plenum Press. 1993, 299-323.
76. Callis, R.T.; Jahrling & DePaoli; P.B. A Pathology of Lassa virus infection in the rhesus monkey. Am. J. Trop. Med. Hyg. 1982, 31, 1038-1045.
77. Jahrling, P. B; Hesse, R.A.; Eddy, G.A.; Johnson, K.M.; Callis, R.T.; Stephen; E.L. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 1980, 141, 580-589.
78. Lange, J. V; Mitchell, S.W.; McCormick, J.B.; Walker, D.H.; Evatt B.L.; Ramsey; R.R. Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am. J. Trop. Med. Hyg. 1985, 34, 999-1007.
79. Kunz, S. The role of the vascular endothelium in arenavirus haemorrhagic fevers. Thromb. Haemost 2009, 102, 1024-1029.
80. Lukashevich, I.S.; I. Tikhonov, I.; Rodas, J.D. Arenavirus-mediated liver pathology: acute lymphocytic choriomeningitis virus infection of rhesus macaques is characterized by high-level interleukin-6 expression and hepatocyte proliferation. J. Virol. 2003, 77, 1727-1737.
81. Lukashevich, I.S.; Rodas, J.D.; Tikhonov, I.I. LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration. Arch. Virol. 2004, 149, 2319-2336.
82. Baize, S.; Marianneau, P.; Loth, P. Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus Monkeys. J. Virol. 2009, 83, 5890-5903.
83. Pannetier, D.; Reynard, S.; Russier, M. Human Dendritic Cells Infected with the Nonpathogenic Mopeia Virus Induce Stronger T-Cell Responses than Those Infected with Lassa Virus. J. Virol. 2011, 85, 8293-8306.
84. Carrion, R.; Jr. Brasky, K.; Mansfield, K. Lassa Virus Infection in Experimentally Infected Marmosets: Liver Pathology and Immunophenotypic Alterations in Target Tissues. J. Virol. 2007, 81, 6482-6490.
85. Zapata, J.C.; Pauza, C.D.; Djavani, M.M. Lymphocytic choriomeningitis virus (LCMV) infection of macaques: A model for Lassa fever. Antivir. Res. 2011, 92, 125-138.
86. Zhou, S.; Kurt-Jones E.A.; Mandell, L.; Cerny, A.; Chan, M.; Golenbock, D.T.; Finberg, R.W. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 2005, 35, 822-830.
87. Zhou, S.; Kurt-Jones, E.A.; Cerny, A.M.; Chan, M.; Bronson, R.T.; Finberg, R.W. MyD88 Intrinsically Regulates CD4 T-Cell Responses. J. Virol. 2009, 83, 1625-1634.
88. Cao, W.; Henry, M.D.; Borrow, P.; Yamada, H.; Elder, J.H.; Ravkov, E.V.; Nichol, S.T.; Compans, R.W.; Campbell, K.P.; Oldstone, M.B.A. Identification of-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 1998, 282, 2079-2081.
89. Kunz, S.; Rojek, J.M.; Kanagawa, M. Posttranslational Modification of {alpha}-Dystroglycan, the Cellular Receptor for Arenaviruses, by the Glycosyltransferase LARGE Is Critical for Virus Binding. J. Virol. 2005, 79, 14282-14296.
90. Oldstone, M.B.A.; Campbell, K.P. Decoding arenavirus pathogenesis: Essential roles for alpha-dystroglycan-virus interactions and the immune response. Virology 2011, 411, 170-179.
91. Imperiali, M.; Spörri, R.; Hewitt, J.; Oxenius, A. Post-translational modification of α-dystroglycan is not critical for lymphocytic choriomeningitis virus receptor function in vivo. J. Gen. Virol. 2008, 89, 2713-2722.
92. Shimojima, M.; Ströher, U.; Ebihara, H.; Feldmann, H.; Kawaoka, Y. Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol. 2012, 86, 2067-2078.
93. Shimojima, M.; Kawaoka, Y. Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein. J. Vet. Med. Sci. 2012, June 1, PMID: 22673088.
94. Clegg, J.C.; Lloyd, G. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever. Lancet. 1987, 2, 186-188.
95. Johnson, K.M.; McCormick, J.B.; Webb, P.A.; Smith, E.S.; Elliot, L.H.; King, I.J. Clinical virology of Lassa fever in hospitalized patient. J. Infect. Dis. 1987, 155, 456-463.
96. Pushko, P.; Geisbert, J.; Parker, M.; Jahrling, P.; Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 2001, 75, 11677-11685.
97. McCormick, J.; Mitchell, S.; Kiley, M.; Ruo, S.; Fisher-Hoch, S. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 1992, 31, 1-7.
98. Lukashevich, I.S.; Clegg, J.C.; Sidibe, K. Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen. J. Med. Virol. 1993, 40, 210-217.
99. Bausch, D.G.; Rollin, P.E.; Demby, A.H. Diagnosis and Clinical Virology of Lassa Fever as Evaluated by Enzyme-Linked Immunosorbent Assay, Indirect Fluorescent-Antibody Test, and Virus Isolation. J. Clin. Microbiol. 2000, 38, 2670-2677.
100. Branco, L. M; Grove, J.N.; Boisen, M.L.; Shaffer, J.G.; Goba, A.; Fullah, M.; Momoh, M.; Grant, D.S.; Garry, R.F. Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol. J. 2011, 8, doi:10.1186/1743-1422X-1188-1478.
101. Krasnianski., V.; Potryvaeva, N.V.; Borisevich, I.V.; Gradoboev, V.N.; Pashanina, T.P.; Pshenichnov, V.A. A trial to produce an inactivated Lassa fever vaccine. Vopr Virusol. 1993, 38(6), 276-279.
102. Branco, L.; Grove, J.; Geske, F. Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virology J. 2010, 7, 279.
103. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. Rev. 2004, 4, 499-511.
104. Takeuchi, O.; Akira, S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 2008, 20, 17-22.
105. Borrow, P.; Martinez-Sobrido, L.; De la Torre, J.C. Inhibition of the Type I Interferon Antiviral Response During Arenavirus Infection. Viruses 2010, 2, 2443-2480.
106. Koyama, S.; Coban, C.; Aoshi, T.; Horii, T.; Akira, S.; Ishii, K.J. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert. Rev. Vaccines. 2009, 8, 1099-10107.
107. Huang, C.; Kolokoltsova, O.A.; Yun, N.E. Junín Virus Infection Activates the Type I Interferon Pathway in a RIG-I-Dependent Manner. PLoS Negl Trop. Dis. 2012, 6, e1659.
108. Habjan, M.; Andersson, I.; Klingström, J. Processing of Genome 5′ Termini as a Strategy of Negative-Strand RNA Viruses to Avoid RIG-I-Dependent Interferon Induction. PLoS ONE 2008, 3, e2032.
109. Walsh, K.; Teijaro, J.R.; Zuniga, E.I.; Welch, M.J.; Fremgen, D.M.; Blackburn, S.D.; von Tiehl K.F.; Wherry, E.J.; Flavell, R.A.; Oldstone, M.B. Toll-like Receptor 7 Is Required for Effective Adaptive Immune Responses that Prevent Persistent Virus Infection. Cell Host Microbe. 2012, 11, 643-653.
110. Macal, M.; Lewis G.M.; Kunz, S.; Flavell, R.; Harker, J.A. Zúñiga EI. Plasmacytoid Dendritic Cells Are Productively Infected and Activated through TLR-7 Early after Arenavirus Infection. Cell Host Microbe. 2012, 11, 617-630.
111. Baz Morelli, A.; Becher, D.; Koernig, S.; Silva, A.; Drane, D.; Maraskovsky, E. ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases. Journal of Medical Microbiology 2012, 61, 935-943.
112. Boesen, A.; Sundar, K.; Coico, R. Lassa Fever Virus Peptides Predicted by Computational Analysis Induce Epitope-Specific Cytotoxic-T-Lymphocyte Responses in HLA-A2.1 Transgenic Mice. Clin. Diagn. Lab. Immunol. 2005, 12, 1223-1230.
113. Botten, J.; Alexander, J.; Pasquetto, V. Identification of Protective Lassa Virus Epitopes That Are Restricted by HLA-A2. J. Virol. 2006, 80, 8351-8361.
114. Botten, J.; Whitton, J.L.; Barrowman, P. A Multivalent Vaccination Strategy for the Prevention of Old World Arenavirus Infection in Humans. J. Virol. 2010, 84, 9947-9956.
115. Liu, F.; Feuer, R.; Hassett, D.E.; Whitton, J.L. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8+ T cell-mediated, TNF-dependent immunopathology. J. Clin. Invest. 2006, 116, 465-475.
116. Strauss, J.; Strauss, E. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 1994, 58, 491-562.
117. Vander Veen, R.L.; Hank Harris, D. L.; Kurt I. Kamrud. Alphavirus replicon vaccines. Animal Health Res. Rev. 2012, doi:10.1017/S1466252312000011.
118. Bergen, M.J.; Pan, C.-H.; Greer, C.E.; Legg, H.S.; Polo, J.M.; Griffin, D.E. Comparison of the Immune Responses Induced by Chimeric Alphavirus-Vectored and Formalin-Inactivated Alum-Precipitated Measles Vaccines in Mice. PLoS ONE 2010, 5, e10297.
119. Carroll, T.; Matzinger, S.R.; Barro, M.; Fritts, L.; McChesney, M.B.; Miller, C.J.; Johnston, R.E. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone® in rhesus macaques. Vaccine 2011, 29, 931-940.
120. Thompson, J.; Whitmore, A.C.; Konopka, J.L.; Collier, M.L.; Richmond, E.M.; Davis, N.L. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 2006, 7, 3722-3727.
121. Thompson, J.; Nicholson M.G.; Whitmore A.C.; Zamora, M.; West, A.; Iwasaki, A. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J. Immunol. 2008, 181, 574-585.
122. Thompson, J.M.; Whitmore, A.C.; Staats, H.F.; Johnston, R.E. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 2008, 26, 4267-4275.
123. Pushko, P.; Parker, M.; Ludwig, G.V.; Davis, N.L.; Johnston, R.E.; Smith, J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 1997, 2, 389-401.
124. Nelson, E.; Prieto, D.; Alexander, T.G.; Pushko, P. Lofts LA, Rayner JO, Kamrud KI, Fralish B, Smith J.F. Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res. Treat. 2003, 82, 169-183.
125. Johnston, R.; Davis, N.; Smith, J.; Pushko, P.; Parker, M.; Ludwig, G. Alphavirus RNA replicon systems. U.S. Patent 7,235,235 2007, Alphavax IP.
126. Pushko, P. Vector platforms derived from the alphavirus vaccines. U.S. Patent Application No. 2006/0198854 2006.
127. Rodriguez-Carreno, M.P.; Nelson, M.S.; Botten, J.; Smith-Nixon, K.; Buchmeier, M.J.;Whitton, J.L. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 2005, 335, 87-98.
128. Grant-Klein, R.; Altamura L.A.; Schmaljohn C.S. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses. Virus Res. 2011, 162, 148-161.
129. Whitton, J.L.; Tishon, A.; Lewicki, H. Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J. Virol. 1989, 63, 4303-4310.
130. Schulz, M.; Aichele, P.; Schneider, R.; Hansen, T.H.; Zinkernagel, R.M.; Hengartner, H. Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide. Eur. J. Immunol. 1991, 21, 1181-1185.
131. Djavani, M.; Yin, C.; Xia, L.; Lukashevich, I. S; Pauza, C.; Salvato, M. Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein. Vaccine. 2000, 18, 1543-1554.
132. Djavani, M.; Yin, C.; Lukashevich, I.; Rodas, J.; Rai, S.; Salvato, M. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J. Hum. Virol. 2001, 4, 103-108.
133. Whitton, J.L.; Sheng, N.; Oldstone, M.B.; McKee, T.A. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. Journal of Virology 1993, 67, 348-352.
134. Saade, F.; Petrovsky, N. Technologies for enhanced efficacy of DNA vaccines. Expert. Rev. Vaccines 2012, 11, 189-2012.
135. Lauring, A.S.; Jeremy O.; Jones, Raul Andino. Rationalizing the development of live attenuated virus vaccines. Nat. Biotechnol. 2010, 28, 573-579.
136. McCormick, J.B.; Fisher-Hoch, S.P. Lassa fever. Curr. Top. Microbiol. Immunol. 2002, 262, 75-109.
137. Lukashevich, I.S.; Patterson, J.; Carrion, R. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 2005, 79, 13934-13942.
138. Ambrosio, A.; Saavedra, M.C.; Mariani, M.A.; Gamboa, G.S.; Maiza, A.S. Argentine hemorrhagic fever vaccines. Human Vaccines 2011, 7, 694-700.
139. Auperin, D.D.; Esposito, A.A.; Lange, J.V. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res. 1988, 9, 233-248.
140. Fisher-Hoch, S. P; Hutwagner, L.; Brown, B.; McCormick, J.B. Effective Vaccine for Lassa Fever. J. Virol. 2000, 74, 6777-6783.
141. Garbutt, M.; Liebscher, R.; Wahl-Jensen, V.; Jones, S.; Möller, P.; Wagner, R.; Volchkov, V.; Klenk, H.D.; Feldmann, H.; Ströher, U. Properties of Replication-Competent Vesicular Stomatitis Virus Vectors Expressing Glycoproteins of Filoviruses and Arenaviruses. J. Virol. 2004, 78, 5458-5465.
142. Geisbert, T.W.; Jones, S.; Fritz, E.A. Development of a new vaccine for the prevention of Lassa Fever. PLoS Medicine 2005, 2, e183.
143. Lukashevich, I. S; Patterson, J; Jr, R.C. Safety, immunogenicity, and efficacy of the ML29 vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26, 5246-5254.
144. Bredenbeek, P.J.; Molenkamp, R.; Spaan, W.J.M. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 2006, 345, 299-304.
145. Jiang, X.; Dalebout, T.J.; Bredenbeek, P.J. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 2011, 29, 1248-1257.
146. Morrison, H.G.; Bauer, S.P.; Lange, J.V.; Esposito, J.J.; McCormick, J.B.; Auperin, D.D. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology 1989, 171, 179-188.
147. Fisher-Hoch, S.P.; McCormick, J.B.; Auperin, D. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 1989, 86, 317-321.
148. Tani, H.; Shigeru, M.; Yoshiharu, M. Development and applications of VSV vectors based on cell tropism. Front Microbiol. 2011, doi: 10.3389/fmicb.2011.00272.
149. Geisbert, T.; Feldmann, H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J. Infect. Dis. 2011, 204,1075-1081.
150. Falzarano, D.; Geisbert, T.W.; Feldmann, H. Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert. Rev. Vaccines. 2011, 10, 63-77.
151. Geisbert, T.W.; Jones, S.; Fritz, E.A. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005, 2, 537-545.
152. Charrel, R.N.; de Lamballerie, X.; Fulhorst, C. F. The Whitewater Arroyo virus: natural evidence for genetic recombination among Tacaribe serocomplex viruses (family Arenaviridae). Virology 2001, 283, 161-166.
153. Riviere, Y.; Oldstone; M.B. Genetic reassortants of lymphocytic choriomeningitis virus: unexpected disease and mechanism of pathogenesis. J. Virol. 1986, 59, 363-368.
154. Bishop, D.H.L.; Beaty, B.J.; Shope, R.E. Recombination and gene coding asignment of bunyaviruses and arenaviruses. Ann. N. Y. Acad. Sci. 1980, 354, 84-106.
155. Riviere, Y.R.; Ahmed, P.J.; Southern, M.J.; Buchmeier & Oldstone; M.B. Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J. Virol. 1985, 55, 704-709.
156. Zhang, L.; Marriott, K.A.; Harnis, D.G.; Aronson, J.F. Reassortant analysis of guinea pig virulence of Pichinde virus variants. Virology 2001, 290, 30-38.
157. Moshkoff, D.; Salvato, M.S.; Lukashevich, I.S. Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 2007, 34, 169-176.
158. Albarino, C.G.; Bird, B.H.; Chakrabarti, A.K.; Dodd, K.A.; Erickson, B.R.; Nichol, S.T. Efficient rescue of recombinant Lassa virus reveals the influence of S segment non-coding regions on virus replication and virulence. J. Virol. 2011, 85, 4020-4024.
159. Hass, M.; Westerkofsky, M.; Muller, S.; Becker-Ziaja, B.; Busch, C.; Gunther, S. Mutational Analysis of the Lassa Virus Promoter. J. Virol. 2006, 80, 12414-12419.
160. Perez, M.; de la Torre, J.C. Characterization of the Genomic Promoter of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus. J. Virol. 2003, 77, 1184-1194.
161. Barr, J.N.; Wertz, G.W. Bunyamwera Bunyavirus RNA Synthesis Requires Cooperation of 3'-and 5'-Terminal Sequences. J. Virol. 2004, 78, 1129-1138.
162. Lukashevich, I.; Djavani, M.; Shapiro, K. The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum. J. Gen. Virol. 1997, 78, 547-551.
163. Lelke, M.; Brunotte, L.; Busch, C.; Gunther, S. An N-Terminal Region of Lassa Virus L Protein Plays a Critical Role in Transcription but Not Replication of the Virus Genome. J. Virol. 2010, 84, 1934-1944.
164. Hastie, K.M.; Kimberlin, C.R.; Zandonatti, M.A.; MacRae, I.J.; Saphire, E.O. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 2396-2401.
165. Qi, X.; Lan, S.; Wang, W. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 2010, 468, 779-783.
166. Martinez-Sobrido, L.; Emonet, S.; Giannakas, P.; Cubitt, B.; Garcia-Sastre, A.; de la Torre, J.C. Identification of Amino Acid Residues Critical for the Anti-Interferon Activity of the Nucleoprotein of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus. J. Virol. 2009, 83, 11330-11340.
167. Martinez-Sobrido, L.; Giannakas, P.; Cubitt, B.; Garcia-Sastre, A.; de La Torre, J.C. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 2007, 81, 12696-12703.
168. Martinez-Sobrido, L.; Zuniga, E.I.; Rosario, D.; Garcia-Sastre, A.; de la Torre, J.C. Inhibition of the Type I Interferon Response by the Nucleoprotein of the Prototypic Arenavirus Lymphocytic Choriomeningitis Virus. J. Virol. 2006, 80, 9192-9199.
169. Hastie, K.M.; Bale, S.; Kimberlin, C.R.; Saphire, E.O. Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr. Opin. Virol. 2012, 2, 151-156.
170. Glushakova, S.E.; Omelyanenko, V.G.; Lukashevitch, I.S. The fusion of artificial lipid membranes induced by the synthetic arenavirus 'fusion peptide'. Biochim. Biophys. Acta. 1992, 1110, 202-208.
171. Klewitz, C.; Klenk, H.-D.; ter Meulen, J. Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity. J. Gen. Virol. 2007, 88, 2320-2328.
172. Moshkoff, D.; Salvato, M.S.; Lukashevich, I.S. Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 2006, 34, 169-176.
173. Kelley, L.A.; & Michael, J.E.S. Protein structure prediction on the Web: a case study using the Phyre server. Nature Protocols 2009, 4, 363-371.
174. Droniou-Bonzom, M.E.; Reignier, T.; Oldenburg, J.E. Substitutions in the Glycoprotein (GP) of the Candid#1 Vaccine Strain of Junin Virus Increase Dependence on Human Transferrin Receptor 1 for Entry and Destabilize the Metastable Conformation of GP. Journal of Virology 2011, 85, 13457-13462.
175. Albariño, C.G.; Bird, B.H.; Chakrabarti, A.K. The Major Determinant of Attenuation in Mice of the Candid1 Vaccine for Argentine Hemorrhagic Fever Is Located in the G2 Glycoprotein Transmembrane Domain. Journal of Virology 2011, 85, 10404-10408.
176. Glushakova, S.E.; Pyzhik, E.V.; Vasiuchkov, A.D.; Erokhina, I.R.; Mar'iankova; R.F. pH-dependent fusion of eukaryotic cells, caused by arenaviruses, pathogenic and non-pathogenic for humans. Mol Gen Mikrobiol Virusol. 1992, 7-8, 27-31.
177. Snoy, P.J. Establishing Efficacy of Human Products Using Animals. Veterinary Pathology Online 2010, 47, 774-778.
178. Goicocheaa, M.A.; Zapata, J.C.; Bryant, J. Davis, H.; Salvato, M.S.; Lukashevich, I.S. Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. Vaccine 2012, 30, 1445-1452.
179. Barkar, N.D.; Lukashevich, I.S. Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections. Vopr. Virusol. 1989, 34, 598-603.
180. Carrion, R.J.; Patterson, J.L.; Johnson, C. A ML29 reassortant virus protects guinea pigs against a distantly-related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 2007, 25, 4093-4102.
181. Lukashevich, I. S; Carrion Jr, R.; Salvato, M.S. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 2008, 26, 5246-5254.
182. Zapata, J.C.; Poonia, B.; Bryant, J.; Davis, H.; Ateh, E.; George, L.; Crasta, O.; Zhang, Y.; Slezak, T.; Crystal Jaing, C.; Pauza, D.; Goicochea, M.; Moshkoff, D.; Lukashevich, I.S.; Salvato, M.S. An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. J. Virol. 2012, submitted.
183. Djavani, M.M.; Crasta, O.R.; Zapata, J.C. Early blood profiles of virus infection in a monkey model for Lassa fever. J. Virol. 2007, 81, 7960-7973.
184. Hayes, E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop. Med. Hyg. 2007, 101, 967-971.
185. Lindsey, N.P.; Schroeder, B.A.; Miller, E.R. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26, 6077-6082.
186. Silva, M. L; Espirito-Santo, L. R; Martins, M.A. Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination. Clin. Vaccine Immunol. 2010, 17, 118-126.
187. Galbraith, S.E.; Barrett, A.D.T. Yellow Fever. In A.D.T. Barrett, L.R. Stanberry Eds., Vaccines for Biodefense and Emerging and Neglected Diseases. Academic Press, Elsevier, Amsterdam, The Netherlands, 2009; pp.753-785.
188. Fisher-Hoch, S.; McCormick, J. Towards a human Lassa fever vaccine. Rev. Med. Virol. 2001, 11, 331-341.
189. Guy, B.; Guirakhoo, F.; Barban, V.; Higgs, S.; Monath, T.P.; Lang, J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28, 632-649.
190. Barba-Spaeth, G.; Longman, R.S.; Albert, M.L.; Rice, C.M. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J. Exp. Med. 2005, 202, 1179-1184.
191. Bonaldo, M.C.; Garratt, R. C; Caufour, P.S. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J. Mol. Biol. 2002, 315, 873-885.
192. Bonaldo, M.C.; Garratt, R.C.; Marchevsky, R.S. Attenuation of Recombinant Yellow Fever 17D Viruses Expressing Foreign Protein Epitopes at the Surface. J. Virol. 2005, 79, 8602-8613.
193. Tao, D.; Barba-Spaeth, G.; Rai, U.; Nussenzweig, V.; Rice, C.M.; Nussenzweig, R.S. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J. Exp. Med. 2005, 201, 201-209.
194. Stoyanov, C.T.; Boscardin, S.B.; Deroubaix, S. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 2010, 28, 4644-4652.
195. Editorial. YF17D vector for Lassa fever vaccine. International Innovation 2010, April, 77-79.
196. Bonaldo, M.; Mello, S.; Trindade, G. Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virology Journal 2007, 4, 115.
197. Bonaldo, M.C.; Martins, M.A.; Rudersdorf, R. Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus Macaques. J. Virol. 2010, 84, 3699-3706.
198. Stoyanov, C.T.; Boscardin, S.B.; Deroubaix, S. Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 2010, 28, 4644-4652.
199. Barban, V.; Girerd, Y.; Aguirre, M. High stability of yellow fever 17D-204 vaccine: A 12-year restrospective analysis of large-scale production. Vaccine 2007, 25, 2941-2950.
200. Monath, T.P.; Myers, G.A.; Beck, R.A. Safety testing for neurovirulence of novel live, attenuated flavivirus vaccines: Infant mice provide an accurate surrogate for the test in monkeys. Biologicals 2005, 33, 131-144.
201. Monath, T.P.; Levenbook, I.; Soike, K. Chimeric Yellow Fever Virus 17D-Japanese Encephalitis Virus Vaccine: Dose-Response Effectiveness and Extended Safety Testing in Rhesus Monkeys. J. Virol. 2000, 74, 1742-1751.
202. Fisher-Hoch, S.P.; Mitchell, S.W.; Sasso, D.R.; Lange, J.V.; Ramsey, R.; McCormick, J.B. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 1987, 155, 465-467.
203. Peters, C.J. Arenaviruses. In: Richman, D. D; Whitley, R.J.; Hayden, F.G. Clinical Virology. Eds. Churchill Livingstone, New York, 1997; pp.779-799.
204. Walker, D.H.; Wulff, H.; Lange, J.V.; Murphy, F.A. Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull. World Health Organ. 1975, 52, 523-534.
205. Hensley, L.E.; Smith, M.A.; Geisbert, J.B. Pathogenesis of lassa fever in cynomolgus macaques. Virol. J. 2011, 8, 205.
206. Carrion, R.J.; Patterson J.L. Vaccines against viral hemorrhagic fevers: non-human primate models. Hum. Vaccin. 2011, 7, 667-673.
207. Mansfield, K. Marmoset model commonly used in biomedical research. Comp. Medicine 2003, 53, 383-392.
208. Gowen, B.B.; Holbrook, M.R. Animal models of highly pathogenic RNA viral infections: Hemorrhagic fever viruses. Antivir. Res. 2008, 78, 79-90.
209. Omatsu, T.; Moi, M.L.; Hirayama, T.; Takasaki, T.; Nakamura, S.; Tajima, S.; Ito, M.; Yoshida, T.; Saito, A.; Katakai, Y.; Akari, H.; Kurane, I. Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: development of high levels of viraemia and demonstration of protective immunity. J. Gen. Virol. 2011, 92, 2272-2280.
210. Firsova, I.; Shatokhina, I. V; Borisevich, I.V.; Evseev, A.A.; Maksimov, V.A.; Pantiukhov, V.B.; Khmelev, A.L. Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever. Vopr Virusol. 2003, 48, 43-45.
211. Flatz, L.; Rieger, T.; Merkler, D.; Bergthaler, A.; Regen, T.; Schedensack, M.; Bestmann, L.; Verschoor, A.; Kreutzfeldt, M.; Brück, W. T cell-dependence of Lassa fever pathogenesis. PLoS Pathogen. 2010, 6, e1000836.
212. Yun, N.E.; Poussard, A.L.; Seregin, A.V.; Walker, A.G.; Smith, J.K.; Aronson, J.F.; Smith, J.N.; Soong, L.; Paessler, S. Functional Interferon System Is Required for Clearance of Lassa Virus. J. Virol. 2012, 86, 3389-3392.
213. Schildknecht, A.; Welti, S.; Geuking, M.B.; Hangartner, L.; van den Broek, M. Absence of CTL Responses to Early Viral Antigens Facilitates Viral Persistence. J. Immunol. 2008, 180, 3113-3121.
214. Carnec, X.; Baize, S.; Reynard, S.; Diancourt, L.; Caro, V.; Tordo, N.; Bouloy, M. Lassa virus nucleoprotein mutants generated by reverse genetics induce robust type I IFN response in human dendritic cells and macrophages. J. Virol. 2011, 85, 12093-12097.
215. Marzi, A.; Feldmann, H. Geisbert, T.W.; Falzarano, D. Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections. J. Bioterror. Biodef. 2011, 10.4172/2157-2526. S4171-4004.
216. Appaiahgari, M.B.S.V. Clinical development of IMOJEV ®-a recombinant Japanese encephalitis chimeric vaccine (JE-CV). Exp. Opin. Biol. Ther. 2012, doi: 10.1517/14712598.14712012.14704908
217. Guy, B.; Barrere, B.; Malinowski, C.; Saville, M.; Teyssou, R.; Lang, J. From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29, 7229-7241.
218. Leroy, E. M; Gonzale, J.P.; Baize, S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin. Microbiol. Infect. 2011, 17, 964-976.
219. McKee, K.T.J.; Enria, D.A.; Barerra-Oro, J.G. Junin (Argentine Hemorrhagic Fever). In: A. D. T. Barett and L. R. Stanberry Eds. Vaccines for Biodefense and Energing and Neglected Diseases. Elsevier, Amsterdam, The Netherlands, 2009; pp. 537-550.
220. Anonymous. Arboviruses and Related Zoonotic Viruses. 2007, www.cdc.gov/biosafety/publications/bmbl5/BMBL5_sect_VIII_f.pdf.